Harbor Capital Advisors Inc. Buys Shares of 181,729 Magenta Therapeutics, Inc. (NASDAQ:MGTA)

Harbor Capital Advisors Inc. bought a new stake in Magenta Therapeutics, Inc. (NASDAQ:MGTAGet Rating) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 181,729 shares of the company’s stock, valued at approximately $805,000. Harbor Capital Advisors Inc. owned 0.31% of Magenta Therapeutics as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of MGTA. Rockefeller Capital Management L.P. bought a new stake in shares of Magenta Therapeutics during the third quarter valued at approximately $26,000. BNP Paribas Arbitrage SA raised its holdings in shares of Magenta Therapeutics by 436.0% during the third quarter. BNP Paribas Arbitrage SA now owns 5,467 shares of the company’s stock valued at $40,000 after buying an additional 4,447 shares during the last quarter. Citigroup Inc. raised its holdings in shares of Magenta Therapeutics by 29.6% during the third quarter. Citigroup Inc. now owns 6,418 shares of the company’s stock valued at $47,000 after buying an additional 1,466 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Magenta Therapeutics by 18.3% during the third quarter. Invesco Ltd. now owns 12,964 shares of the company’s stock valued at $95,000 after buying an additional 2,005 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Magenta Therapeutics during the third quarter valued at approximately $107,000. Institutional investors own 59.13% of the company’s stock.

NASDAQ MGTA traded down $0.02 on Tuesday, hitting $1.90. 4,527 shares of the stock were exchanged, compared to its average volume of 305,672. Magenta Therapeutics, Inc. has a 52-week low of $1.91 and a 52-week high of $13.22. The company has a market cap of $111.72 million, a P/E ratio of -1.47 and a beta of 2.01. The business’s 50-day moving average price is $2.93.

Magenta Therapeutics (NASDAQ:MGTAGet Rating) last posted its quarterly earnings data on Tuesday, March 8th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.01). As a group, equities research analysts expect that Magenta Therapeutics, Inc. will post -1.46 earnings per share for the current fiscal year.

MGTA has been the topic of several recent analyst reports. B. Riley dropped their target price on Magenta Therapeutics from $13.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, January 24th. Zacks Investment Research raised Magenta Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, March 11th. Mizuho dropped their target price on Magenta Therapeutics from $17.00 to $8.00 and set a “buy” rating on the stock in a report on Monday. The Goldman Sachs Group raised Magenta Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $7.00 to $8.00 in a report on Wednesday, January 5th. Finally, BTIG Research dropped their target price on Magenta Therapeutics from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Monday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $9.04.

Magenta Therapeutics Profile (Get Rating)

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants.

Read More

Want to see what other hedge funds are holding MGTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Magenta Therapeutics, Inc. (NASDAQ:MGTAGet Rating).

Institutional Ownership by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.